|MDACC Study No:||2010-0167 (clinicaltrials.gov NCT No: NCT01134120)|
|Title:||A Phase I Study of LY2784544 in Patients with JAK2 V617F-Positive Myeloproliferative Disorders|
|Principal Investigator:||Srdan Verstovsek|
|Treatment Agent:||JAK2 Inhibitor; LY2784544|
|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
of LY2784544 that can be given to patients with myeloproliferative disorders.
The safety of this drug will also be studied.